Sernova's CEO Dr. Philip Toleikis Featured on BNN
20 June 2014 - 8:00PM
Marketwired
Sernova's CEO Dr. Philip Toleikis Featured on BNN
LONDON, ONTARIO--(Marketwired - Jun 20, 2014) - Sernova Corp.
(TSX-VENTURE:SVA), a clinical stage company developing disruptive
medical technologies for the long-term treatment of chronic
diseases such as diabetes and haemophilia today was featured on BNN
by news anchor Francis Horodelski.
Please refer to the segment using the following link:
http://www.bnn.ca/Video/player.aspx?vid=384318
About
Sernova
Sernova Corp. is a clinical stage regenerative medicine company
developing medical technologies for the treatment of chronic
debilitating metabolic diseases such as diabetes, blood disorders
including haemophilia and other diseases treated through
replacement of proteins or hormones missing or in short supply
within the body. Sernova is developing the Cell Pouchâ„¢, an
implantable medical device for therapeutic cells (donor, xenogeneic
or stem cells) which then release proteins and/or hormones as
required. The therapeutic cells are protected from immune attack by
Sernova's proprietary technologies.
Forward-Looking Information
This release may contain forward-looking statements.
Forward-looking statements are statements that are not historical
facts and are generally, but not always, identified by the words
"expects", "plans", "anticipates", "believes", "intends",
"estimates", "projects", "potential" and similar expressions, or
that events or conditions "will", "would", "may", "could" or
"should" occur. Although Sernova believes the expectations
expressed in such forward-looking statements are based on
reasonable assumptions, such statements are not guarantees of
future performance and actual results may differ materially from
those in forward looking statements. Forward-looking statements are
based on the beliefs, estimates and opinions of Sernova's
management on the date such statements were made. Sernova expressly
disclaims any intention or obligation to update or revise any
forward-looking statements whether as a result of new information,
future events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Sernova Corp.Philip Toleikis, Ph.D.President and CEO(604)
961-2939philip.toleikis@sernova.com /
info@sernova.comwww.sernova.comRay Matthews & AssociatesRay
Matthews(604) 818-7778www.raymatthews.ca
Sernova (TSXV:SVA)
Historical Stock Chart
From Oct 2024 to Nov 2024
Sernova (TSXV:SVA)
Historical Stock Chart
From Nov 2023 to Nov 2024